News & Events

On August 8, 2024, Guangzhou Lupeng Pharmaceutical Co., Ltd. (Lupeng Pharma), an innovative pharmaceutical company focusing on malignant tumors and autoimmune diseases，and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), China's leading innovation-driven pharmaceutical company, jointly announced that the two parties have entered into a licensing agreement on a small molecule Bruton's tyrosine kinase inhibitor (BTKi) LP-168 (“LP-168”) independently developed by Lupeng Pharma .

ASH Joint Program Committees have selected two LP-168 clinical abstracts in NHL and MCL, and one LP-118 preclinical study in MCL for poster presentations at the 65th ASH Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. LP-168 is a novel next generation BTK inhibitor, and LP-118 is a new generation dual Bcl-2/Bcl-xL inhibitor invented by Guangzhou Lupeng Pharmaceutical Co., Ltd.. Abstracts are available on the ASH website.

ASH Joint Program Committees have selected two LP-168 clinical abstracts in NHL and MCL for poster presentations at the 65th ASH Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. LP-168 is a novel next generation BTK inhibitor invented by Guangzhou Lupeng Pharmaceutical Co., Ltd.. Abstracts are available on the ASH website.

ASH Joint Program Committees have selected LP-168 preclinical and clinical abstracts for oral presentations at the 65th ASH Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. LP-168 is a novel next generation BTK inhibitor invented by Guangzhou Lupeng Pharmaceutical Co., Ltd.. Abstracts are available on the ASH website.

Wednesday, January 12, 2022 (EST), Lupeng Pharmaceuticals presented at the 40th Annual J.P. Morgan Healthcare Conference. Dr. Stephen Anthony, the CMO of US/EU/UK Oncology Operation, gave a presentation on behalf of the company. Dr. Anthony shared the fast-growth of Lupeng in the past few years, including the key milestones achieved in several projects and the development of an innovative anti-cancer pipeline, which attracted the attention of many domestic and international companies.